Source study unconfirmed
Story checked
Kidney Week 2026 features late-breaking clinical trials in kidney care (opens in a new tab)
news-medical.net · 2026-10-24
Short answer
Source study unconfirmedStudy not confirmed.
The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Kidney Week 2026 features late-breaking clinical trials in kidney care
news-medical.net · 2026-10-24
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
No single source study could be confirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
View article claimsSearch result
Source study unconfirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
Source layer
The 8 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Also referencedpresented as the new finding
Post-Authorization Efficacy and Safety (PAES): An Open-Label Post-Authorization Trial of 50 Imlifidase Crossmatch-Positive Deceased-Donor Kidney Transplants in Europe
- Also referencedpresented as the new finding
High-Dose Cholecalciferol and Clinical Outcomes in Patients Receiving Dialysis: Results of the SIMPLIFIED Trial
- Also referencedpresented as the new finding
ATTACK (Aspirin To Target Arterial events in Chronic Kidney Disease): A Multicentre Randomised Trial of Aspirin vs. Usual Care for the Primary Prevention of Cardiovascular Events in Patients with CKD
- Also referencedpresented as the new finding
Vadadustat Three Times Weekly for the Treatment of Anemia in Patients Receiving Hemodialysis
- Also referencedpresented as the new finding
Effects of Ravulizumab on Proteinuria and Hematuria in Patients with IgAN: A Prespecified Interim Analysis of the Phase 3 I CAN Trial
- Also referencedpresented as the new finding
Sefaxersen, a Novel mRNA-Targeted Therapy for IgA Nephropathy: Interim Analysis of the Phase 3 IMAgINATION Trial
- Also referencedpresented as the new finding
SWIFT: A Phase 3 Cluster-Randomized Registry Trial of Symptom Monitoring vs. Usual Care in Patients with Hemodialysis
- Also referencedpresented as the new finding
HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 9Not checkedThe American Society of Nephrology selected several late-breaking clinical trials to be presented in-person at Kidney Week 2026, covering transplantation, dialysis treatment, and emerging therapies for kidney diseases and comorbidities.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 9Not checkedIn the PAES open-label post-authorization trial, imlifidase converted positive crossmatches to negative and enabled kidney transplantation in highly sensitized patients, with excellent graft function at 1 year, though antibody-mediated rejection may develop after transplantation.View evidenceHide evidence
As stated50 crossmatch-positive deceased-donor kidney transplants
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 9Not checkedIn the SIMPLIFIED trial, high-dose vitamin D every 2 weeks did not significantly reduce overall death risk or cardiovascular hospitalizations, infections, or fractures compared with standard care in people on dialysis, though there was a possible suggestion of benefit in non-white patients and in men.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 9Not checkedIn the ATTACK trial, aspirin may provide an overall net clinical benefit for primary prevention of cardiovascular events in people with chronic kidney disease, but the authors say the trial was substantially smaller than planned and they cannot be certain.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 9Not checkedIn a pragmatic randomized clinical trial, vadadustat was as effective as erythropoiesis-stimulating agent therapy for maintaining hemoglobin in patients on dialysis and was associated with a 16% increase in favorable outcomes, driven primarily by reduced hospitalization rates, with no difference in overall survival.View evidenceHide evidence
As stated16% increase in favorable outcomes
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 9Not checkedIn the phase 3 I CAN trial, ravulizumab produced rapid, clinically meaningful, statistically significant reductions in urinary protein-to-creatinine ratio in adults with primary IgA nephropathy, with favorable effects on hematuria, biomarkers, and remission rates, while the effect on eGFR is still to be assessed.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 7 of 9Not checkedIn the phase 3 IMAgINATION trial, sefaxersen significantly reduced proteinuria in patients with IgA nephropathy and evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 8 of 9Not checkedIn the phase 3 SWIFT trial, regular symptom assessment with feedback increased symptom conversations but did not improve health-related quality of life or fatigue in adults receiving maintenance hemodialysis.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 9 of 9Not checkedIn a phase 2 randomized controlled trial, HLX79/E-602 plus rituximab produced the fastest and most complete responses in membranous nephropathy compared with rituximab alone or lower-dose combinations, and the combination was well tolerated.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Highly sensitized kidney transplant candidates: integrating acceptable mismatch, desensitization, imlifidase, and emerging immune-cell targeting strategies.
Frontiers in Immunology · 2026 · PubMed, Europe PMC
A Successful Pediatric Kidney Transplant in a Highly Sensitized Recipient with Compassionate Use of Imlifidase: A Case Study with One Year Follow Up
American Journal of Transplantation · 2025 · Crossref
Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients.
Transplant International : Official Journal of the European Society for Organ Transplantation · 2025 · PubMed, Europe PMC
429.2: Imlifidase in highly sensitized kidney transplant recipients with a positive crossmatch against a deceased donor - results of the French ISKIA registry.
Transplantation · 2026 · Crossref
Molecular Diagnosis of Early Equivocal Alloimmune Injury After Imlifidase Desensitization in a Kidney Transplant Recipient.
2026 · Europe PMC